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Hypothalamic hamartomas (HH) are rare, benign congenital tumors associated with intractable epilepsy. Most cases are sporadic and
nonsyndromic. Approximately 5% of HH cases are associated with Pallister-Hall syndrome (PHS), which is caused by haploinsufﬁciency
of GLI3. We have investigated the possibility that HH pathogenesis in sporadic cases is due to a somatic (tumor-only) mutation in GLI3.
We isolated genomic DNA from peripheral blood and surgically resected HH tissue in 55 patients with sporadic HH and intractable
epilepsy. A genome-wide screen for loss of heterozygosity (LOH) and chromosomal abnormalities was performed with parallel analysis
of blood and HH tissue with Affymetrix 10K SNP microarrays. Additionally, resequencing and ﬁne mapping with SNP genotyping were
completed for the GLI3 gene with comparisons between peripheral blood and HH tissue pairs. By analyzing chromosomal copy-number
data for paired samples on the Affymetrix 10K array, we identiﬁed a somatic chromosomal abnormality on chromosome 7p in one HH
tissue sample. Resequencing ofGLI3 did not identify causative germlinemutations but did identify LOHwithin theGLI3 gene in the HH
tissue samples of three patients. Further genotyping of 28 SNPs within and surrounding GLI3 identiﬁed ﬁve additional patients exhibit-
ing LOH. Together, these data provide evidence that the development of chromosomal abnormalities within GLI3 is associated with the
pathogenesis of HH lesions in sporadic, nonsyndromic patients with HH and intractable epilepsy. Chromosomal abnormalities includ-
ing the GLI3 locus were seen in 8 of 55 (15%) of the resected HH tissue samples. These somatic mutations appear to be highly variable.Introduction
Hypothalamic hamartomas (HH [MIM 241800]) are un-
common, benign congenital tumors, associated with
refractory epilepsy, and occur in approximately one in
200,000 children and adolescents.1 Symptoms resulting
from HH include gelastic seizures, cognitive deﬁcits, and
behavioral abnormalities.2 This phenotype is highly asso-
ciated with the intrahypothalamic anatomic type of HH,
whereas the parahypothalamic type usually results in cen-
tral precocious puberty only.3–5 A progressive clinical
course with worsening of seizures, cognition, and behavior
is seen in at least 50% of cases.6–8 Those with onset of ep-
ileptic seizures during infancy appear to be at greatest risk
for this deteriorating natural history. Approximately 40%
of patients with the intrahypothalamic type of HH also
have central precocious puberty.9
MostHHpatients develop thedisease ona sporadic,nonfa-
milial basis. However, HH is described in association with
a number of different dysmorphic syndromes.10 Of these,
by far the most common is Pallister-Hall syndrome (PHS
[MIM 146510]), which accounts for approximately 5% of all
HH patients with epilepsy.8 Clinical features of PHS include
HH, central or postaxial polydactyly, imperforate anus, and
biﬁdepiglottis.11Affectedpedigrees indicateautosomal-dom-
inant inheritance with variable expressivity, although most
cases are sporadic and represent newmutations.12
Linkage analysis of large PHS pedigrees suggested a sus-
ceptibility locus at 7p13.13 Utilizing a candidate gene ap-366 The American Journal of Human Genetics 82, 366–374, Februaproach, the same group reported that two affected families
had frameshift (loss-of-function) mutations in GLI3 (MIM
165240), a zinc-ﬁnger transcription factor within the sonic
hedgehog intracellular signaling pathway.14
Although HH occurs in PHS as a result of a genomic mu-
tation, we have investigated the possibility that HH in
sporadic, nonsyndromic cases results from a somatic (tu-
mor-only) chromosomal abnormality or GLI3 mutation.
We have completed a genome-wide screen for loss of het-
erozygosity (LOH) with comparison of single-nucleotide
polymorphism (SNP) microarrays of DNA derived from
blood and resected HH tissue from sporadic, nonsyn-
dromic patients. Additionally, we have resequenced the
GLI3 coding sequences and performed ﬁne mapping with
SNPs neighboring GLI3, comparing DNA derived from
blood and HH tissue in sporadic HH cases. Our ﬁndings
identify somatic GLI3 mutations in sporadic HH cases,
suggesting a role in the etiology of HH lesions.
Material and Methods
Clinical Proﬁle of Study Subjects
Blood and HH tissue samples for DNA studies were obtained from
55 sporadic, nonsyndromic HH patients undergoing surgical
resection of HH for refractory epilepsy at our institution between
February 2003 and October 2005. Fifteen patients were female
(27%), and 40 were male (73%). The mean age at time of evalua-
tion and surgical treatment was 13.8 years (median 11.8 years,
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three antiepilepsy drugs [AEDs]) was present in 100% of patients.
The mean age at ﬁrst onset of seizures was 1.1 years (range <0.1 to
7.0 years). However, 28 (51%) patients had onset of gelastic sei-
zures before 1 month of age by retrospective history. All patients
(100%) had gelastic seizures at some time during the clinical
course, although 44 (80%) had developed at least one additional
seizure type by the time of surgery (mean 2.8 seizure types per
patient in those with multiple seizure types). Seizure frequency
was at least 1 per day in 50 patients (91%) and at least 1 per
week in the remaining ﬁve patients (9%).
Developmental retardation (IQ or developmental quotient less
than 70) was present in 35 patients (64%). A prior history of cen-
tral precocious puberty had occurred in 18 patients (33%). Ana-
tomic type of the HH lesion, according to the classiﬁcation system
proposed by Delalande and Fohlen,15 was type I in four (7%), type
II in 35 (64%), type III in 11 (20%), and type IV in ﬁve (9%). The
meanHH lesion volumewas 3.25 cm3 (median 1.25 cm3, range 0.1
to 28.3 cm3). Two patients (3%) had magnetic resonance (MR)
imaging abnormalities in addition to the HH lesion, with periven-
tricular nodular heterotopias in both.
Sample Collection
Genomic DNA was isolated from fresh whole blood samples, ob-
tained prior to surgery. Surgically resected HH tissue specimens
were immediately immersed in RNAlater (Applied Biosystems, Fos-
ter City, CA) and frozen at 80C. At the time of study, genomic
DNA was isolated with the Gentra Puregene DNA Puriﬁcation
Kit for whole tissue (Gentra Systems, Minneapolis, MN) according
to the manufacturer’s protocol. DNA concentration was deter-
mined with a GeneQuant spectrophotometer (Biochrom, Cam-
bridge, UK).
Whole-Genome SNP Microarrays
SNP genotyping was performed with the GeneChip Mapping 10K
Array and Assay Kit (Affymetrix, Santa Clara, CA).16 All incuba-
tions were done with a Tetrad thermal cycler (MJ Research, Cam-
bridge, MA). Internal positive and negative controls were per-
formed in parallel with the supplied genomic DNA (Affymetrix).
Two-hundred ﬁfty nanograms of double-stranded genomic DNA
was digested with XbaI (New England Biolabs, Ipswitch, MA) for
2 hr at 37C, and heat inactivation for 20 min at 70C followed.
Digested DNA was then incubated with a 0.25 M Xba adaptor (Af-
fymetrix) and DNA ligase (New England Biolabs) in standard liga-
tion buffer (New England Biolabs) for 2 hr at 16C, and heat inac-
tivation for 20 min at 70C followed. Ligated products were
ampliﬁed in quadruplicate with 0.5 M the supplied generic primer
XbaI (Affymetrix) in PCR Buffer II (Applied Biosystems) with
2.5 mM MgCl2, 2.5 mM deoxynucleosides (dNTPs), and 10 units
of AmpliTaq Gold polymerase (Applied Biosystems) under the
following polymerase chain reaction (PCR) conditions: 95C for
5 min, then 35 cycles (95C for 20 s, 59C for 15 s, and 72C for
15 s) and a ﬁnal extension at 72C for 7 min. Fragments in the
250 to 1000 basepair size range are preferentially ampliﬁed under
these conditions. PCR products were puriﬁed with the QIAquick
PCR puriﬁcation kit (QIAGEN, Valencia, CA) according to the
manufacturer’s recommendations, with the exception of the elu-
tion procedure. DNA from each of four PCR replicate samples
was bound to separate columns and washed. The eluant collected
from column one was used for the elution of the remaining three
columns in series. The ﬁnal puriﬁed product is the combination of
four puriﬁed PCR product samples. Eighteen to twenty micro-The Amgrams of puriﬁed PCR products were fragmented with 0.24 units
of the supplied GeneChip Fragmentation Reagent (Affymetrix)
for 30 min at 37C, and a heat inactivation for 15 min at 95C fol-
lowed. Samples were then labeled with 102 units of terminal deox-
ytransferase (Affymetrix) and 0.143 mM of supplied GeneChip
DNA Labeling Reagent in TdT buffer (Affymetrix) for 2 hr at
37C and then 15 min at 95C. After the end labeling, the frag-
ments were hybridized to a GeneChip HumanMapping 10K Array
for 16–18 hr at 48C while rotating at 60 rpm. Microarrays were
washed with the Fluidics Station 450 (Affymetrix) in 0.63 sodium
chloride, sodium phosphate, and ethylenediaminetetraacetic acid
(SSPE), and a three-step staining protocol followed. We incubated
the arrays ﬁrst with 10 mg/ml streptavidin (Pierce Biotechnology,
Rockford, IL), washed the arrays with 63 SSPE and incubated
with 5 mg/ml biotinylated antistreptavidin (Vector Laboratories,
Burlingame, CA) and 10 mg/ml streptavidin-phycoerythrin conju-
gate (Molecular Probes, Invitrogen, Carlsbad, CA), and ﬁnally
washed the arrays with 63 SSPE, per the manufacturer’s recom-
mended times. Microarrays were scanned with the GeneChip
Scanner 3000 according to the manufacturer’s protocol (Affyme-
trix). Data acquisition was performed with the GeneChip GCOS
software (Affymetrix). Prior to publication, we did explore the util-
ity of other higher density arrays for ﬁne mapping the GLI3 locus
with sample 2030 and 450S DUO arrays (Illumina, San Diego) by
using 150 ng of DNA, otherwise following manufacture recom-
mendations. We did not attempt additional samples on this or
other platforms because of limitations in available nonampliﬁed
DNA. Call rates of 98.1% and 99.1% were obtained for tissue
and blood, respectively, with a reduced quantity of starting geno-
mic DNA (150 ng versus 750 ng). Unfortunately, no informative
heterozygote SNPswere found, and the region could not be further
mapped. Investigation of probe intensity at the homozygote SNPs
did not show evidence for a change in copy number, suggesting
that tandem loss of an allele and duplication resulting in no net
copy-number change is a possible mechanism for the LOH ob-
served in the Sanger resequencing and two methods of SNP geno-
typing with this sample. The 450S data does further rule out con-
tamination, degradation, or other experimental artifacts for this
sample because LOH was not observed elsewhere, consistent
with the Affymetrix 10K results.
GLI3 Resequencing
GLI3 encompasses approximately 250 kb across 15 exons on chro-
mosome 7p13. GLI3 was ampliﬁed by PCR with 2.5 mM dNTPs,
2 units of AmpliTaq Gold polymerase (Applied Biosystems), 3 mM
MgCl2, 5% dimethyl sulfoxide (DMSO), 13 PCR Buffer, an anneal-
ing temperature of 51.8C, and an extension time of 1 min, and
was cycled 35 times with a Tetrad thermal cycler (MJ Research,
Cambridge,MA) (see Table 1). AmpliﬁedGLI3 product was puriﬁed
after thermocycling with the AmPure PCR puriﬁcation kit (Agen-
court Biosciences, Beverly, MA), resulting in the removal of unin-
corporated dNTPs, primers, and salts. PCR products were eluted in
30 ml distilled H2O. Both strands of each PCR product were se-
quenced as follows: Sequencing reactions were performed with
3 ml (approximately 25 ng) of puriﬁed PCR product in a 6 ml reac-
tion containing 0.33 ml BigDye Terminator v3.1 premix (Applied
Biosystems), 3.2 pmol of either M13 forward (50-TGTAAAACGAC
GGCCAGT-30) or M13 reverse (50-CAGGAAACAGCTATGACC-30)
primer, and 1.03 ml 53 BigDye sequencing buffer. Cycle sequenc-
ing was performed for 35 cycles following the manufacturer’s
recommendations on GeneAmp 9700 PCR machines (Applied
Biosystems). Sequencing reactions were puriﬁed with CleanSEQerican Journal of Human Genetics 82, 366–374, February 2008 367
Table 1. Primer Sets for Amplification
Primer Sequence Primer Name Primer Sequence Primer Name
50-TGGCCAGACCTAAGAAATGC-30 Exon 1a Forward 50-TTGATTCCACATGGAAAAGTTG-30 Exon 1a Reverse
50-TGTGGAATCAAGAGCGTGTT-30 Exon 1b Forward 50-TTTTAAAGCCACGTCTGCAA-30 Exon 1b Reverse
50-GCAGACGTGGCTTTAAAAAGTA-30 Exon 1c Forward 50-CAAAAGTCCACTTCACCTGTCA-30 Exon 1c Reverse
50-TTTGGAAAGTTGATGGCTCTG-30 Exon 2 Forward 50-GCAAACGCTCAATTCACAAG-30 Exon 2 Reverse
50-GGGAGAGGGATATCGAGAATG-30 Exon 3 Forward 50-GGAAAGTGGAAAGAAAATTACACC-30 Exon 3 Reverse
50-TTGCTTTGTGAATCGGAATG-30 Exon 4 Forward 50-TTCAGTGAACCCACGAACAG-30 Exon 4 Reverse
50-AGAGACAGCCTCTGCCTGTG-30 Exon 5 Forward 50-GGCACATGGGAAACACTCAC-30 Exon 5 Reverse
50-AATTGCTGATGTGGGTTGTG-30 Exon 6 Forward 50-TTTGCCATTTCCCAAGACTC-30 Exon 6 Reverse
50-TCTTCCACGTAGGCAAGTAGC-30 Exon 7 Forward 50-TTCTTCCTCATAGGCAGTTGG-30 Exon 7 Reverse
50-GCTGCAGATCTTGTGTACTTGTC-30 Exon 8 Forward 50-GAGGCTGTGAGAACACAGAGG-30 Exon 8 Reverse
50-GCCAAATAAGACCGCTTGTC-30 Exon 9 Forward 50-GGAACTGCCGTGAAAAAGAC-30 Exon 9 Reverse
50-TTGTCTTCCCTCCTGTTGTG-30 Exon 10 Forward 50-CAATGCGGCTCCTAAGAAAC-30 Exon 10 Reverse
50-TGGGGTATTTTCTGCATTTTC-30 Exon 11 Forward 50-ACCGAGGCATTTATCACCAG-30 Exon 11 Reverse
50-CAACTTGGAGGGCGTGTTAG-30 Exon 12 Forward 50-TCCCACCTAGGAAGCTCAAG-30 Exon 12 Reverse
50-CCTCAAAGCCTTGTGAAAGTG-30 Exon 13 Forward 50-CCCTCTATGCACCCTACCTG-30 Exon 13 Reverse
50-GAGCTCTCATTATTGGC-30 Exon 14 Forward 50-ACTGGTGGAGAAACTAGC-30 Exon 14 Reverse
50-TTGCTCATGCCTGGTGTAAG-30 Exon 15a Forward 50-TCTTCAGGCTCATCCTCTCC-30 Exon 15a Reverse
50-ACTCCTACGACCCCATCTCC-30 Exon 15b Forward 50-ATCGTTCAGGTTGGCATCAG-30 Exon 15b Reverse
50-CAGTCCCGAAACTTCCACTC-30 Exon 15c Forward 50-ACCGTAGGGGTTGCTGTTC-30 Exon 15c Reverse
50-CTCCTCCAAGCTCAAGTGTG-30 Exon 15d Forward 50-CTGGCCCTTGGTAGATGTTG-30 Exon 15d Reverse
50-GGTAGCGCCAAATGAGTCAG-30 Exon 15e Forward 50-CGTGTCTTGCTGACTGAAGC-30 Exon 15e Reverse
50-GCAGTCAGGACAGCTCAGTG-30 Exon 15f Forward 50-GAACTCATGTCCCCGATAGC-30 Exon 15f Reverse
50-GACCACTCCAGCCTGATGTC-30 Exon 15g Forward 50-GTTAGGTGAGATGAGATTGC-30 Exon 15g Reverse
M13 tails were added for sequencing of GLI3.(Agencourt Biosciences) for the removal of unincorporated dye ter-
minators and analyzed on 3730xl DNA analyzers (Applied Biosys-
tems). Mutations were detected by analysis of sequences traces
withMutation Surveyor software (Soft Genetics, State College, PA).
Fine Mapping SNP Genotyping
In order to identify the extent and boundaries of LOH, we used
a melting temperature (Tm)-shift SNP genotyping method, where
GC tails of different lengths were attached onto the 50 end of al-
lele-speciﬁc primers.17 On the basis of the melting temperature
of the PCR product, SNP alleles can be distinguished, and geno-
types can be assigned on the basis of the melting-curve data.
Primers were designed on the basis of the methodology used by
Wang et al.17 In brief, for every SNP analyzed, we designed two for-
ward allele-speciﬁc primers, with the 30 end of the primer repre-
senting one of the SNP base pairs along with one common reverse
primer. A 14 base pair GC clamp (50-GCGGGCAGGGCGGC-30)
was attached to the allele-speciﬁc primer that had the higher Tm
base (C or G), and a 6 base pair GC clamp (50-GCGGGC-30) was at-
tached to the primer with the lower Tm base (A or T). Ideally, for-
ward primers were 15–20 bp long (our average length was 19 bp)
and had a melting temperature ranging from 59C–62C without
the GC clamp (our average Tm was 50C). Common reverse
primers were designed no more than 20 base pairs downstream
from the SNP and had an optimal length of 22–27 bp (our average
length was 25 bp) with a melting temperature between 63C and
70Cwithout the GC clamp (our average Tmwas 57C). PCRs were
set up as follows in 15 ml volumes: 10 ng of genomic DNA; 0.2 mM
each of the three primers, 1.8 U of Taq Gold, 10 mM Tris-HCl (pH
8), 40 mM KCl, 2 mMMgCl2, 50 mM each dATP, dCTP, and dGTP;
25 mMdTTP; 75 mM dUTP; 0.23 SYBR Green nucleic acid gel stain;
5%DMSO; and 2.5% glycerol. PCR andmelting-curve analysis was
preformed in Hard-Shell Thin-Wall 96-Well Microplates (Bio-Rad
Laboratories, Hercules, CA) and sealed with Flat Cap Strips (Bio-
Rad). PCR was performed on the DNA Tetrad Engine 2 (MJ Re-368 The American Journal of Human Genetics 82, 366–374, Februasearch). An initial incubation step at 95C for 6 min was followed
by 40 cycles of a three-step ampliﬁcation process, which consists
of 20 s at 95C for denaturation, 30 s at 59C (or optimal primer
temperature) for annealing, and 30 s at 72C for extension. Sam-
ples were then incubated for 10 min at 72C for ﬁnal extension.
Melting-curve analysis was preformed on the Opticon continuous
ﬂuorescence detection system (MJ Research). Samples were ﬁrst in-
cubated at 55C for 5 s. Fluorescence intensity was then detected
with a melting curve from 60C to 92C. Readings were taken
every 0.2C and held for 1 s between reads. We selected 43 SNPs
for genotyping by using the Tm-shift method. Of these, 28 SNPs
gave reliable calls across a control set of DNA samples and were
used for genotyping blood and tissue pairs.
Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) was performed for the assess-
ment of copy-number variation at the GLI3 locus in a patient
(2020; Figure 1) for the conﬁrmation of the chromosomal abnor-
mality found by copy-number analysis of high-density SNP geno-
typing. qPCR was not conducted on other samples because of lim-
itations on nonampliﬁed genomic DNA. The assay was performed
on the My iQ single-color real-time PCR detection system (Bio-
Rad) in Thermo-fast 96-well semi-skirted plates (Abgene, Epsom,
UK) with iQ SYBR Green Supermix (Bio-Rad). Reaction mixtures
consisted of 10 ng of DNA in 6 ml or 10 ml of SYBRGreen Supermix,
and 4 ml of 2 mM primer pair. Primer sequences are as follows:
50-GTTGCACAAAGGCCTACTCG-30 and 50-CGTTCTGTTTTGGTG
TTTGG-30 (directed against exon 12 of GLI3); and 50- GCTTCAGT
CAGCAAGACACG-30 and 50-TGTCCACTGTGCTTGTCACC-30 (di-
rected against exon 15 of GLI3). The assay was performed with
DNA isolated from both blood and HH tissue samples, and reac-
tions were run in quadruplicate with the following conditions:
95C for 5 min and then 40 cycles (95C for 20 s and 60C for
20 s). Melting-curve analysis was performed with readings taken
every 1C from 60C to 95C, with a dwell time of 5 s. b-actinry 2008
Figure 1. Chromosomal Abnormalities on 2020
Blood and tissue pairs were assayed on the Affymetrix 10K platform. Copy-number changes were calculated with the analysis software
DChipSNP.19 The amplification was later verified at the GLI3 locus by qPCR.
(A) Copy-number analysis indicated that chromosome 7p had a copy number change to 2.5 copies for the tissue and not the blood,
whereas all other samples showed no significant stretches of copy-number change. The assay was repeated for verification that the finding
was not assay specific.
(B) The percent of SNPs receiving a No Call across a 50 SNP window is shown for sample 2020. It would be expected that the No Call rate
would increase in a region containing an amplification because SNPs would not easily bin into AA, AB, and BB, as would be the case if the
copy number were two or one. Within the 7p region is the GLI3 gene, previously shown to harbor germline mutations causing Pallister Hall
syndrome, which is highly associated with HH.(ACTB [MIM 102630]) was used as the endogenous control, with
the following primer pair: 50-GGACTTCGAGCAAGAGATGG-30
and 50- AAGGAAGGCTGGAAGAGTGC-30. Copy number was
calculated with the 2-DDCT method as described.
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Results
Whole-Genome Screening for LOH and Altered
Copy Number
To identify somatic chromosomal abnormalities speciﬁc to
HH tissue, we genotyped each of 26 blood and HH tissue
pairs on the Affymetrix 10K GeneChip SNP genotyping
microarrays. By utilizing this platform, we could (1) iden-
tify stretches of LOH where SNPs were heterozygous in
blood and homozygous in tissue and (2) assess for copy-
number changes by analyzing probe-intensity data.
Quality Control for Affymetrix 10K Genotype Data
Genotype data underwent a two-stage strict quality-
control ﬁlter so that accuracy could be ensured. QualityThe Amcontrol was ﬁrst employed at a sample level. Of the 26
paired blood and HH tissue samples, 21 samples passed
a strict quality-control metric of having greater than
90% of all genotypes called for both blood and HH tissue
samples. However, those samples not passing the 90%
threshhold were also inspected by copy-number analysis
in DChipSNP19 and by preferential biases for SNPs that
were not called. In this inspection, we were speciﬁcally as-
sessing whether a large chromosomal abnormality was
contributing to the low call rate. For those ﬁve samples,
there was no evidence for chromosomal abnormalities
contributing to the lower call rate. It is likely that these
samples failed because of limited or poor DNA quality.
Overall call rate for those samples passing the quality con-
trol metric was 93.2%. Quality-control ﬁltering was also
applied at the SNP level. The call rate for each SNP across
blood samples was calculated, and SNPs with less than
95% call rate were removed from further analysis. After
this two-stage ﬁlter, 7833 SNPs giving high-quality data
remained.20erican Journal of Human Genetics 82, 366–374, February 2008 369
Analysis for Chromosomal Abnormalities
The paired blood and HH tissue samples of the 21 samples
from above were examined for chromosomal abnormali-
ties with DChipSNP. Rather than analyzing exclusively
genotype data, DChipSNP uses probe-intensity data com-
pared to a reference, or reference samples, to estimate
copy number.19 Previous studies and our own efforts
have found that DChipSNP can effectively detect both de-
letions and ampliﬁcations covering multiple SNPs on Affy-
metrix arrays.21 The exact lower limit is to our knowledge
not known, and is likely dependent on coverage and SNP
behavior.
For the 21 paired blood and HH tissue samples, only one
sample exhibited strong evidence for a chromosomal ab-
normality, showing an ampliﬁcation on chromosome 7p.
Interestingly, inspection of the underlying copy-number
estimates ﬁnds that the SNPs within the region generally
average about 2.5 copies, with an estimate of 1.8 copies
for the remainder of chromosome 7, and also on other
chromosomes. Because copy-number analysis is not proven
to be quantitatively accurate, we also inspected genotype
data. If the region was ampliﬁed, we would also expect an
increase in No Calls for SNPs within this region because
SNPs would fall out of the three class (AA, AB, and
BB) bins utilized by the MPAM (modiﬁed partitioning
around medoids) Affymetrix GeneChip calling algorithm.
In an ampliﬁed region, genotypes that are AAB, ABB, etc.
would likely receive No Calls, because they would fall out
of the genotype-calling silhouette.22 Consistent with an
ampliﬁcation at 7p and shown in Figure 1, we ﬁnd that
there is a sharp increase in the percent of SNPs receiving
a No Call within a 50 SNP sliding window, peaking at
nearly 18%, whereas the genome-wide No Call rate is 6%
(p ¼ 2 3 1010). These two analyses provide independent
evidence for an ampliﬁcation of 7p in HH tissue in this sin-
gle case. To conﬁrm the ampliﬁcation speciﬁcally within
the GLI3 locus, we designed qPCR reactions for the 12th
and 15th exons as described in the methods. Copy num-
bers of 3.97 and 4.23 for exons 12 and 15, respectively,
were calculated with the 2-DDCT method,18 conﬁrming
the chromosomal abnormality by a separate method.
Genome-Wide Analysis for Loss of Heterozygosity
Because both whole-blood and HH tissue genotype data
were available, we examined paired samples for LOH at
a genome-wide level. A change of genotype from heterozy-
gous in blood to homozygous in HH tissue constitutes an
LOH event. Given the number of SNPs and samples geno-
typed, some LOH events are expected because of the num-
ber of markers genotyped. For the 21 paired samples across
the 7833 SNPs, we observed a mean of 8.2 LOH events per
paired sample (range 1–22 LOH events per paired sample).
This number of LOH events is expected given the reported
genotype error rate of the platform (~0.2%). Consequently,
we made the additional requirement that two consecutive
LOH events must occur at informative SNPs. The proba-
bility of two consecutive LOH events will be less than370 The American Journal of Human Genetics 82, 366–374, Februar1 3 105 for any one sample. Across all samples, we did
not observe two consecutive LOH events within any paired
set, establishing that large-scale LOH is not observed in
paired blood andHH tissue samples. Considering the num-
ber of SNPs analyzed, an approximately 30% rate of SNP
heterozygosity, and that LOH was only determined signif-
icant if it occurred in two consecutive LOH events (ignor-
ing SNPs homozygous in blood), the resolution of this
analysis is approximately 2 Mb (mean 1.81 Mb separation
between two heterozygous SNPs). Thus, we conclude that
large-scale somatic deletions do not contribute to the path-
ogenesis of HH lesions in sporadic, nonsyndromic cases.
GLI3 Resequencing in Blood and HH Tissue Pairs
Within the region exhibiting the chromosomal abnormal-
ity, we sequenced the exon and promoter regions for GLI3
across 55 blood and HH tissue pairs with the objective of
identifying germline and/or somatic mutations. Bidirec-
tional sequence data were analyzed with Mutation Sur-
veyor (SoftGenetics, State College, PA).
Based upon GLI3 resequencing on genomic DNA iso-
lated from peripheral blood, one case was identiﬁed
with a germline mutation that had not been previously
cataloged. This was a missense mutation in exon 15,
leading to a serine to isoleucine substitution. This HH pa-
tient was a nondysmorphic, high-functioning adult female
with refractory gelastic seizures as her only seizure type.
Consequently, this mutation is more likely to be a benign
polymorphism. It appears unlikely that germline muta-
tions in GLI3 lead to sporadic and otherwise nonsyn-
dromic HH.
However, we did ﬁnd evidence for loss of heterozygosity
in the blood and HH tissue pairs, consistent with somatic
mutations in HH tissue. Speciﬁcally, within 3 of the 55
(5%) sequenced blood and HH tissue pairs, LOH was ob-
served at a resequenced SNP. Summarized as part of Fig-
ure 2, LOH was observed by direct resequencing on exon
7 of patient 2038, exon 15 of patient 2075, and exon 5
of patient 2030. In all cases, we repeated sequence reac-
tions and used bidirectional sequence traces to conﬁrm
that the LOH event was accurate. The ﬁnding of LOH in
3/55 individuals is likely an underestimate because a het-
erozygote SNP (or other polymorphisms) was required to
identify loss of one allele. Thus, given this additional evi-
dence for LOH in GLI3, we selected a panel of 43 SNPs
for custom genotyping by using the Tm-shift technique.
Additional Custom Genotyping of GLI3
Because of the limited capability of resequencing to iden-
tify LOH, we genotyped an additional set of SNPs across
the GLI3 gene. Sufﬁcient unampliﬁed genomic DNA was
available for 26 of the 55 blood and HH tissue pairs.
The same 26 pairs were utilized for the whole-genome mi-
croarray screening reported above. We selected SNPs with
40%–50% heterozygosity to provide approximate even
coverage across GLI3 by using HapMap resource.23
We constructed and validated assays by following they 2008
Figure 2. Observed Loss of Heterozygosity within GLI3 Gene for HH Blood and Tissue Paired Samples
LOH was detected either by resequencing, genotyping on the Affymetrix platform, or custom SNP-genotyping with Tm-Shift assays. LOH
events were defined as pairs in which the blood sample contained a heterozygous polymorphism (e.g., a heterozygote SNP) and the tissue
sample was homozygous. SNPs that were genotyped homozygous in blood were uninformative (shown as gray bars). Samples where a het-
erozygote was observed in both the tissue and blood samples indicate the absence of LOH.
(A) A total of eight samples contained LOH events observed by either genotype data from the Affymetrix 10K GeneChip mapping array
(yellow bar), sequencing of a heterozygous SNP within exons (green bar), or SNP genotyping (red bar). Blue bars indicate the nearest
flanking SNP to an LOH even (green, yellow, and red bars) where LOH was definitively not observed. Uninformative SNPs that were
not within a region of LOH or SNPs that were heterozygous in blood and tissue but did not neighbor an LOH event are not shown, for
clarity.
(B) Schematic of GLI3 gene aligned to above LOH graphs.
(C) Mutations within the GLI3 gene have previously been found to lead to Pallister-Hall Syndrome (PHS).Tm-shift method as described by Wang17 for 28 SNPs
across the GLI3 gene. Assays were validated by the dem-
onstration of distinct calls for all possible genotype calls
across a control panel of HapMap samples. Genotype call-
ing was manually accomplished by the inspection of all
samples and the visual identiﬁcation of three classes of
Tm-shift peaks. Any genotyped SNP was informative
only if the blood sample gave a heterozygote call. Of
the 26 HH patients, consistent and reliable calls could
be obtained for 24.
LOH events within GLI3 were observed in 6 of 24 blood
and HH tissue pairs (25%) by custom SNP genotyping
(Figure 2). The endpoint of a putative LOH region was de-
termined by the identiﬁcation of ﬂanking SNPs that wereThe Amheterozygous in both blood and HH tissue. For example,
for patient 2030, multiple LOH events are surrounded by
two SNPs that were heterozygous in blood and tissue.
Flanking SNPs were not identiﬁed for some samples whose
most proximal or distal SNP was either homozygous in
both blood and tissue or an LOH event.
Considering all three genotyping techniques together,
one patient [patient 2030, (Figure 2)] demonstrated a total
of nine LOH events in the GLI3 region by whole-genome
microarray screening, GLI3 resequencing, and ﬁne map-
ping of GLI3 by SNP genotyping. Patients 2033 and 2020
(Figure 2) exhibited two LOH events each. All other pa-
tients had one observed LOH event identiﬁed. SNPs exhib-
iting LOH and bounding SNPs for which both blood anderican Journal of Human Genetics 82, 366–374, February 2008 371
tissue showed heterozygosity at the same base are listed in
Table 2.
Discussion
Although uncommon, hypothalamic hamartomas are an
important model of human epilepsy.8,24 It is the single
best model for subcortical epilepsy in humans. Utilizing
surgically resected HH tissue, it is also an excellent model
for the study of basic molecular and cellular mechanisms
that result in intrinsic epileptogenesis.25,26
PHS is the most common dysmorphic syndrome associ-
ated with HH.10 HH is a hallmark, if not a universal feature
of PHS.27 PHS is associated with mutations within GLI3,
a zinc-ﬁnger transcription factor within the sonic hedge-
hog intracellular signaling pathway.14 GLI3 is located at
7p13 and consists of 15 exons, with the majority of the
coding sequence found in the last two exons.28 A geno-
type-phenotype relationship has been described for GLI3,
which is known to function normally as either an activator
or repressor of gene expression in response to sonic hedge-
hog signaling.27,29 Speciﬁcally, Greig cephalopolysyndac-
taly syndrome (GCPS [MIM 175700]), a dysmorphic syn-
drome with polydactyly and craniofacial anomalies but
without HH) results from loss-of-function mutations in
speciﬁc regions of the gene that result in haploinsufﬁ-
ciency of the gene.29 Alternatively, PHS patients have mu-
tations in themiddle third of the coding region of the gene
that result in a protein that fails to respond to normal
regulatory control.29 Consequently, in PHS, the protein
functions in a constitutively active manner as a repressor
of those genes under its downstream control.30
The genetic mechanism(s) that result in HH in sporadic,
nonsyndromic cases is unknown. We ﬁrst performed a ge-
nome-wide screen with SNP microarrays, looking for LOH
and/or copy-number changes as evidence of a somatic (tu-
mor-only) mutation. LOH in HH tissue (versus blood) typ-
ically implies a deletion of one of the two heterozygous
alleles at a known SNP locus. The presence of LOH at





2075 257307GT/GGSeq rs2051935, rs7782675
2081 rs4724083 n/a, rs10263647
2028 rs2051935 rs1181740A, rs10263647
2020 rs2051935, rs7776918 rs1181740A, rs3898405






2038 183130CT/CCSeq rs7782675, rs1367590
2033 rs9648515, rs99497 rs10263647, rs846312A
Superscript ‘‘A’’ indicates found by Affymetrix, and superscript ‘‘Seq’’ indi-
cates found by sequencing; all others were found by SNP genotyping.372 The American Journal of Human Genetics 82, 366–374, Februarycontiguous informative SNPs implies a deletion event, al-
though other complex chromosomal abnormalities could
also lead to the observation of LOH at a given SNP. In
our initial genome-wide analysis for LOH, we did not
observe consecutive LOH events in any of the samples.
Occasional sporadic LOH events at a given SNP were
observed, though entirely consistent with the Affymetrix
error rate. However, analysis of genome-wide SNP microar-
ray copy-number data did demonstrate one large chromo-
somal abnormality in HH tissue, consisting of an ampliﬁ-
cation of the short arm of chromosome 7 [see (Figure 1)].
Because this was observed in only a single case, the signif-
icance of this ﬁnding for other sporadic, nonsyndromic
HH cases is limited, though it warrants further investiga-
tion. The region spanned several million base pairs,
which is too large to enable a candidate gene approach
(although it is notable that this stretch of DNA does
include GLI3).
On the basis of n this large-scale chromosomal abnor-
mality limited to chromosome 7p, further study focused
on the possibility of acquiring somatic mutations within
GLI3 in HH tissue. By resequencing and custom SNP geno-
typing of the GLI3 locus, we identiﬁed LOH events within
eight blood and HH tissue pairs from a total study group of
55 HH cases (15%). Utilizing GLI3 resequencing, we iden-
tiﬁed possible somatic mutations in 3 of 55 cases (5%),
whereas SNP genotyping determined possible somatic mu-
tations in 6 of 24 cases (25%). Furthermore, genotyping on
the Affymetrix 10K platform found one LOH event in 24
cases within GLI3. One case (2030) was identiﬁed by all
three methods within the GLI3 gene. Noteworthy, LOH
was restricted to the GLI3 gene and was not prevalent in
a genome-wide scan by the Affymetrix 10K for this individ-
ual. Taken together, these results ﬁnd that somatic chro-
mosomal abnormalities occur at the GLI3 locus within
HH tissue and help shed light onto potential mechanisms
for HH pathogenesis. LOH results from the acquisitions of
somatic mutations at one or both of the copies of GLI3,
resulting in an uneven balance of the two alleles. This
ﬁnding is consistent with the ﬁnding that PHS is known
to result from haploinsufﬁciency of GLI3, but future
research is needed to determine the mechanism by which
somatic mutations in GLI3 contribute to the development
of HH.14
However, as noted above, a rather speciﬁc genotype-phe-
notype model has been proposed for the GLI3 gene, with
Pallister-Hall syndrome (and its association with HH) oc-
curring secondary to loss-of-function mutations with the
middle third of the coding region (open reading frame
[ORF] nucleotides [nt] 1998–3481 found in exons 13, 14,
and 15), resulting in the loss of a regulatory domain.27,29
The somatic LOH events found in sporadic HH were
mostly found to span exons 12, 13, 14, and 15. The tech-
nology used in this study and the expectation that chro-
mosomal abnormalities leading to LOH would span large
regions (>1 KB) make it difﬁcult to distinguish breakpoints
within these exons. This is particularly the case for exons2008
14 and 15, wherein most of the coding sequence lies and
where previous PHS mutations are described. Rather, it
can be said there appeared to be a preferential bias for
detecting LOH in exons 14 and 15, previously linked to
PHS. We did not observe any LOH events in the exons 1
through 3. Although there does appear to be a relationship
between sporadic HH lesions and somatic mutations in
GLI3 in at least a subset of patents, it is also apparent
that there is a high degree of variability in these mutations
because no single patient had the same somatic mutation
of the eight cases identiﬁed in this population. This is con-
sistent with other solitary lesions, such as the large number
of different somatic mutations that can occur in the VHL
tumor suppressor gene (MIM 608537) in sporadic clear
cell renal carcinoma.31 Further reﬁnements in genotyping
technology might allow for the identiﬁcation of somatic
mutations of GLI3 in a higher percentage of cases.
Nevertheless, these results would also suggest that most
sporadic HH cases are not due to a somatic mutation of
GLI3 and that another mechanism, or multiple other
mechanisms, including the possibility of somatic muta-
tion in other genes or regions, is responsible. This is also
consistent with other disease models. Sporadic pheochro-
mocytoma, for example, has been associated with somatic
mutations in VHL, RET (MIM 164761), or SBHD genes,
each in a relatively small proportion of cases.32–34
One other candidate gene has been implicated in HH
pathogenesis in patients with HH associated with other de-
velopmental anomalies. Loss-of-function mutations in
SOX2 (MIM 184429), a transcription factor in the SOX
family that makes use of an HMG box DNA-binding do-
main, has been associated with a spectrum of abnormali-
ties, including developmental eye defects (anophthal-
mia and microphthalmia), anterior pituitary hypoplasia,
and other midline cerebral defects. A recent report de-
scribes HH lesions (without an associated history of epi-
lepsy) in two of eight cases (25%) with germline mutations
in SOX2.35 It is unknown whether somatic mutations in
SOX2 are associated with HH in sporadic, nonsyndromic
cases. An additional susceptibility locus for HH has also
been reported, on the basis of the observation of a small
duplication or deletion at 6p25.1–25.3 in a patient with
HH, refractory epilepsy, and subtle dysmorphic features.36
This affected region includes FOXC1 (MIM 601090), a tran-
scription factor in the forkhead family, as a possible candi-
date gene for HH pathogenesis.
The ﬁndings reported here provide evidence that so-
matic mutation in GLI3 is a potential etiology for the
occurrence of HH associated with epilepsy in sporadic,
nonsyndromic patients. Depending upon the speciﬁc
genotyping technology used to compare genomic DNA
derived from peripheral blood and HH tissue, we have ob-
served LOH in the region of GLI3 in 5% to 25% of patients
undergoing surgical resection of HH for refractory epilepsy.
Conversely, a genome-wide screen for LOH demonstrates
that large-scale somatic deletions are not associated with
sporadic HH.The AmAcknowledgments
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